Evolving treatment options for melanoma brain metastases

被引：77

作者：

Ajithkumar, Thankamma ^{[1
]}

Parkinson, Christine ^{[1
]}

Fife, Kate ^{[1
]}

Corrie, Pippa ^{[1
]}

Jeff, Sarah ^{[1
]}

机构：

[1] Cambridge Univ Hosp Natl Hlth Serv Fdn Trust, Dept Oncol, Cambridge CB2 OQQ, England

来源：

LANCET ONCOLOGY | 2015年 / 16卷 / 13期

关键词：

MALIGNANT-MELANOMA; RADIATION-THERAPY; OPEN-LABEL; RANDOMIZED-TRIAL; CEREBRAL METASTASES; SINGLE METASTASES; POSITIVE MELANOMA; PHASE-II; IPILIMUMAB; RADIOTHERAPY;

D O I：

10.1016/S1470-2045(15)00141-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Melanoma is a leading cause of lost productivity due to premature cancer mortality. Melanoma frequently spreads to the brain and is associated with rapid deterioration in quality and quantity of life. Until now, treatment options have been restricted to surgery and radiotherapy, although neither modality has been well studied in clinical trials. However, the new immune checkpoint inhibitors and molecularly targeted agents that have been introduced for treatment of metastatic melanoma are active against brain metastases and off er new opportunities to improve disease outcomes. New challenges arise, including how to integrate or sequence multiple treatment modalities, and current practice varies widely. In this Review, we summarise evidence for the treatment of melanoma brain metastases, and discuss the rationale and evidence for combination modalities, highlighting areas for future research.

引用

页码：E486 / E497

页数：12

共 83 条

[51]

Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]

[52]

Lebbé C, 2010, ANN ONCOL, V21, P401

[53] Response assessment criteria for brain metastases: proposal from the RANO group [J].

Lin, Nancy U. ;

Lee, Eudocia Q. ;

Aoyama, Hidefumi ;

Barani, Igor J. ;

Barboriak, Daniel P. ;

Baumert, Brigitta G. ;

Bendszus, Martin ;

Brown, Paul D. ;

Camidge, D. Ross ;

Chang, Susan M. ;

Dancey, Janet ;

de Vries, Elisabeth G. E. ;

Gaspar, Laurie E. ;

Harris, Gordon J. ;

Hodi, F. Stephen ;

Kalkanis, Steven N. ;

Linskey, Mark E. ;

Macdonald, David R. ;

Margolin, Kim ;

Mehta, Minesh P. ;

Schiff, David ;

Soffietti, Riccardo ;

Suh, John H. ;

van den Bent, Martin J. ;

Vogelbaum, Michael A. ;

Wen, Patrick Y. .

LANCET ONCOLOGY, 2015, 16 (06) :E270-E278

[54] Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial [J].

Long, Georgina V. ;

Trefzer, Uwe ;

Davies, Michael A. ;

Kefford, Richard F. ;

Ascierto, Paolo A. ;

Chapman, Paul B. ;

Puzanov, Igor ;

Hauschild, Axel ;

Robert, Caroline ;

Algazi, Alain ;

Mortier, Laurent ;

Tawbi, Hussein ;

Wilhelm, Tabea ;

Zimmer, Lisa ;

Switzky, Julie ;

Swann, Suzanne ;

Martin, Anne-Marie ;

Guckert, Mary ;

Goodman, Vicki ;

Streit, Michael ;

Kirkwood, John M. ;

Schadendorf, Dirk .

LANCET ONCOLOGY, 2012, 13 (11) :1087-1095

[55] Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial [J].

Maio, Michele ;

Grob, Jean-Jacques ;

Aamdal, Steinar ;

Bondarenko, Igor ;

Robert, Caroline ;

Thomas, Luc ;

Garbe, Claus ;

Chiarion-Sileni, Vanna ;

Testori, Alessandro ;

Chen, Tai-Tsang ;

Tschaika, Marina ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) :1191-1196

[56] Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial [J].

Margolin, Kim ;

Ernstoff, Marc S. ;

Hamid, Omid ;

Lawrence, Donald ;

McDermott, David ;

Puzanov, Igor ;

Wolchok, Jedd D. ;

Clark, Joseph I. ;

Sznol, Mario ;

Logan, Theodore F. ;

Richards, Jon ;

Michener, Tracy ;

Balogh, Agnes ;

Heller, Kevin N. ;

Hodi, F. Stephen .

LANCET ONCOLOGY, 2012, 13 (05) :459-465

[57] Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery [J].

Mathew, Maya ;

Tam, Moses ;

Ott, Patrick A. ;

Pavlick, Anna C. ;

Rush, Stephen C. ;

Donahue, Bernadine R. ;

Golfinos, John G. ;

Parker, Erik C. ;

Huang, Paul P. ;

Narayana, Ashwatha .

MELANOMA RESEARCH, 2013, 23 (03) :191-195

[58]

Mintz AH, 1996, CANCER, V78, P1470, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO

[59]

2-X

[60] A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of maliqnant melanoma [J].

Mornex, F ;

Thomas, L ;

Mohr, P ;

Hauschild, A ;

Delaunay, MM ;

Lesimple, T ;

Tilgen, W ;

Bui, BN ;

Guillot, B ;

Ulrich, J ;

Bourdin, S ;

Mousseau, M ;

Cupissol, D ;

Bonneterre, ME ;

de Gislain, C ;

Bensadoun, RJ ;

Clavel, M .

MELANOMA RESEARCH, 2003, 13 (01) :97-103

← 1 2 3 4 5 6 7 8 9 →